Waypoint Wealth Counsel’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$392K Buy
339
+15
+5% +$17.7K 0.23% 76
2026
Q2
$389K Sell
324
-140
-30% -$143K 0.24% 70
2026
Q1
$427K Sell
464
-314
-40% -$318K 0.22% 97
2025
Q4
$836K Buy
778
+59
+8% +$56.4K 0.31% 58
2025
Q3
$549K Buy
719
+90
+14% +$67K 0.22% 86
2025
Q2
$490K Sell
629
-163
-21% -$127K 0.24% 64
2025
Q1
$654K Buy
792
+161
+26% +$134K 0.41% 42
2024
Q4
$487K Sell
631
-17
-3% -$14.1K 0.32% 54
2024
Q3
$574K Buy
648
+107
+20% +$96.2K 0.39% 48
2024
Q2
$490K Buy
541
+8
+2% +$6.4K 0.37% 45
2024
Q1
$415K Buy
533
+31
+6% +$22.1K 0.32% 52
2023
Q4
$293K Buy
502
+20
+4% +$11.7K 0.25% 70
2023
Q3
$259K Buy
482
+3
+0.6% +$1.55K 0.24% 71
2023
Q2
$225K Buy
+479
New +$201K 0.2% 79

Other funds holding LLY

Waypoint Wealth Counsel's LLY Position: Q3 2026 in Review

Waypoint Wealth Counsel increased its Eli Lilly (LLY) stake by 4.6% in Q3 2026, buying an estimated $17.7K and bringing the position to 339 shares worth $392K. The position accounts for 0.23% of the portfolio, ranked #76.

Waypoint Wealth Counsel first reported a position in LLY in Q2 2023 and has held it in 14 quarters since. The position peaked at $836K in Q4 2025. 3,033 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Waypoint Wealth Counsel held 339 shares of Eli Lilly worth $392K as of Q3 2026.
  • Waypoint Wealth Counsel bought 15 Eli Lilly shares in Q3 2026, an estimated $17.7K.
  • Eli Lilly made up 0.23% of Waypoint Wealth Counsel's portfolio in Q3 2026, its #76 holding.
  • Waypoint Wealth Counsel first reported a position in Eli Lilly in Q2 2023 and has held it in 14 quarters since.
  • Waypoint Wealth Counsel's Eli Lilly position peaked at $836K in Q4 2025.
  • 3,033 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q3 2026, filed 22 Oct 2026.